Analysts Offer Insights on Healthcare Companies: uniQure N.V. (NASDAQ: QURE), Galmed Pharmaceuticals (NASDAQ: GLMD) and CRH Medical Corporation (NYSEARCA: CRHM)

By George MacDonald

There’s a lot to be optimistic about in the Healthcare sector as 3 experts just weighed in on uniQure N.V. (NASDAQ: QURE), Galmed Pharmaceuticals (NASDAQ: GLMD) and CRH Medical Corporation (NYSEARCA: CRHM) with bullish sentimens.

uniQure N.V. (NASDAQ: QURE)

Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on uniQure NV (NASDAQ: QURE) today and set a price target of $26. The company’s shares opened today at $7.10, close to its 52-week low of $6.75.

According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -16.4% and a 26.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Bellicum Pharmaceuticals, and Voyager Therapeutics Inc.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $23

.
Galmed Pharmaceuticals (NASDAQ: GLMD)

H.C. Wainwright analyst Ed Arce reiterated a Buy rating on Galmed Pharmaceuticals (NASDAQ: GLMD) today and set a price target of $22. The company’s shares opened today at $4.61, close to its 52-week low of $3.50.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.9% and a 34.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Sucampo Pharmaceuticals, and Conatus Pharmaceuticals.

Galmed Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $22

.
CRH Medical Corporation (NYSEARCA: CRHM)

In a report released today, Richard Close from Canaccord Genuity reiterated a Buy rating on CRH Medical Corporation (NYSEARCA: CRHM), with a price target of $5. The company’s shares opened today at $3.82.

According to TipRanks.com, Close is a 3-star analyst with an average return of 2.2% and a 47.9% success rate. Close covers the Technology sector, focusing on stocks such as Castlight Health, Evolent Health, and Athenahealth.

CRH Medical Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $5

.